The goal of this clinical trial is to learn if Human Umbilical Cord Mesenchymal Stem Cell (HUCMSC) derived secretome injection is safe and effective in patient with liver cirrhosis. The main questions it ams to answer are: 1. How safe is secretome Injection as an adjuvant therapy for liver cirrhosis patients? 2. How effective is secretome injection in liver fibrosis 6 months after injection? 3. Does secretome injection improve liver function after 6 months after Injection? 4. Does secretome injection affect Child Turcotte Pugh score? 5. How does secretome affect pro inflammatory and anti Inflammatory cytokine in patient with liver cirrhosis? 6. How does secretome injection affect the quality of life in live cirrhosis patient? 7. What is the relationship between secretome injection and encephalopathy? Researchers will compare secretome injection group (patients who recieve secretome injections) to best practice treatment group (patient who receive supportive treatment including hepatoprotector and ursodeoxycolic acid) Researchers will compare the intervention group (patients who are injected with HUCMSC derived secretome) and control group (patients who are only monitored and given their usual drugs) Patients will: Be injected with secretome or take hepatoprotector and ursodeoxycolic acid every 2 weeks for 4 months. Do several test such us fibroscan, stroop test, psychometric hepatic encephalopathy score, short form 36 questionnaire, IL-6, TNF alfa and blood test for albumin, SGOT, SGPT, direct bilirubin, indirect bilirubin, INR, creatinine, ureum, hemoglobin, hematocrite, leukocyte, and thrombocyte. Visit the clinic once every two weeks to receive drugs and treatment for 4 months. Follow up visit to review treatment progress on 3rd months (2 weeks post treatment), 7th months (3 months post treatment),10th months (6 months post treatment)
Age range
17 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Changes in Fibroscan and M2BPGi six month after secretome injections
Timeframe: From enrollment to the end of treatment at 4 months, From enrollment to the end of study at 10 months
Changes in Complete Blood Count and Kidney function after secretome injections
Timeframe: From enrollment to the end of treatment at 4 months, From enrollment to the end of study at 10 months
Changes of albumin, SGOT and SGPT levels in six month after secretome injections
Timeframe: From enrollment to the end of treatment at 4 months, From enrollment to the end of study at 10 months